Cancer Immunotherapeutics Program ABSTRACT The mission of the Cancer Immunotherapeutics (CI) Program is to develop novel immunotherapy interventions that harness patients? immune responses for more specific and less toxic cancer therapies, and translate them into clinical practice. To achieve this goal, the Program has three themes: 1) Develop approaches to enhance efficacy of adoptive T cell therapy and cancer vaccines; 2) Modulate the tumor microenvironment to enhance immunotherapy; and 3) Develop novel antibody therapies and imaging modalities. Within each of these themes, research is ongoing to reduce health disparities within our catchment area. Led by Peter Lee, MD and Hua Yu, PhD, the CI Program spans basic, translational, and clinical research. To translate discoveries into therapies, the CI Program receives support from the City of Hope Comprehensive Cancer Center (COHCCC) through the GMP Manufacturing Core, consisting of three cGMP manufacturing facilities that can produce clinical grade antibody-based therapeutics and small molecule drugs. Targeted recruits with national prominence have added both depth and breadth to the program and include Drs. Mingye Feng, Edwin Manuel, Kim Margolin, Laleh Melstrom, Javier Ogembo, Susanne Warner, Yanghee Woo, and Weiping Zou. The major areas of research focus in the CI Program are strengthened by extensive collaborations with other investigators at COHCCC as well as collaborations with investigators at other academic institutions and industry. Sponsored activities include monthly research meetings, monthly seminars, an annual retreat, and annual pilot funding. Membership: 21 Program Members representing 7 basic and clinical departments Publications: 176 total. 18.2% intra-programmatic; 64.8% inter-programmatic; 35.8% inter-institutional Funding: $4,177,832 peer-reviewed; $2,134,027 of which is NCI funding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-37
Application #
9849211
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Li, Sihui; Ali, Shafat; Duan, Xiaotao et al. (2018) JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells. Cell Rep 23:389-403
Pang, Ka Ming; Castanotto, Daniela; Li, Haitang et al. (2018) Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy. Nucleic Acids Res 46:e6
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609
Bzymek, Krzysztof P; Puckett, James W; Zer, Cindy et al. (2018) Mechanically interlocked functionalization of monoclonal antibodies. Nat Commun 9:1580
Nguyen, Huong Q; Ruel, Nora; Macias, Mayra et al. (2018) Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. J Pain Symptom Manage 56:709-718
Mendez-Dorantes, Carlos; Bhargava, Ragini; Stark, Jeremy M (2018) Repeat-mediated deletions can be induced by a chromosomal break far from a repeat, but multiple pathways suppress such rearrangements. Genes Dev 32:524-536
Zhang, Jing; He, Zhiheng; Sen, Subha et al. (2018) TCF-1 Inhibits IL-17 Gene Expression To Restrain Th17 Immunity in a Stage-Specific Manner. J Immunol 200:3397-3406

Showing the most recent 10 out of 1396 publications